Phenoxy-hydroxypropylamines, method and pharmaceutical preparations for treating cardiovascular diseases

ABSTRACT

Para-substituted phenoxy-hydroxypropylamines having the general formula   AND PHARMACEUTICALLY ACCEPTABLE, NON-TOXIC ACID ADDITION SALTS THEREOF, WHEREIN R&#39;&#39; is an isopropyl or tertiarybutyl radical; Z is a member selected from the group consisting of -OR&#39;&#39;&#39;&#39;, -SR&#39;&#39;&#39;&#39;, and -NHCOOR&#39;&#39;&#39;&#39;, R&#39;&#39;&#39;&#39; being a straight or branched lower alkyl radical having 1 to 3 carbon atoms; and n is 1, 2, or 3, are disclosed as are methods for their preparation. Pharmaceutical preparations are prepared whose active ingredients include at least one of the newly discovered phenoxy-hydroxypropylamine compounds. Therapeutically effective doses of these preparations selectively block the Beta -receptors of the heart making them useful in treating heart diseases in animals including humans.

United States Patent [1 1 Brandstrom et al.

[ Dec. 23, 1975 PHENOXY-HYDROXYPROPYLAMINES,

METHOD AND PHARMACEUTICAL PREPARATIONS FOR TREATING CARDIOVASCULAR DISEASES [75] Inventors: Arne Elof Brandstrom; Per Arvid Emil Carlsson, both of Goteborg;

Stig Ake Ingemar Carlsson, Molnlycke; Hans Rudolf Corrodi, Sodertalje; Lars Ek, Onsala; Bengt [21] Appl. No.: 433,450

Related US. Application Data [60] Division of Ser. No. 342,749, March 19, 1973, Pat. No. 3,873,600, Continuation-impart of Ser. No. 115,851, Feb. 16, 1971, abandoned.

[52] US. Cl 424/300; 424/330 [51] Int. Cl. A61K 31/27 [58] Field of Search 424/300; 260/471 C [56] References Cited UNITED STATES PATENTS 3,712,927 1/1973 Howe et a] 260/471 C Primary Examiner-Stanley J. Friedman Attorney, Agent, or Firm-Brumbaugh, Graves, Donohue & Raymond [57] ABSTRACT Para-substituted phenoxy-hydroxypropylamines having the general formula and pharmaceutically acceptable, non-toxic acid addition salts thereof, wherein R is an isopropyl or tertiarybutyl radical; Z is a member selected from the group consisting of OR", SR", and -NH- COOR", R being a straight or branched lower alkyl radical having 1 to 3 carbon atoms; and n is l, 2, or 3, are disclosed as are methods for their preparation. Pharmaceutical preparations are prepared whose active ingredients include at least one of the newly discovered phenoxy-hydroxypropylamine compounds. Therapeutically effective doses of these preparations selectively block the B-receptors of the heart making them useful in treating heart diseases in animals including humans.

18 Claims, N0 Drawings PHENOXY-HYDROXYPROPYLAMINES; METHOD AND PHARMACEUTICAL PREPARATIONS FOR TREATING CARDIOVASCULAR DISEASES This is a divisional applicationvof our copending application Ser. No. 342,749, filed Mar. 19, 1973, which issued as US. Pat. No. 3,873,600 on Mar. 25, 1975, which was in turn, a continuation-in-part of our previously copending application, Ser. No. 115,851, filed Feb. 16, 1971, now abandoned.

The present invention relates to phenoxy-hydroxypropylamines and, in particular, to para-substituted phenoxy-hydroxypropylamines and methods for their preparation. The invention also relates to the preparation of pharmaceutical preparations containing such para-substituted phenoxyhydroxypropylamines as active ingredients and to a method for the pharmacological use of such compounds. l B-Receptor blocking agents such as propranolol,

alprenolol,

(Iva OCI-l -CH-CH NHCH(CH 1 II CH2-CHCH2 and oxprenolol,

-CH2-CH-CH2-NHCH(C H3)2 0-CH2-CH=CH2 (II'I') have been shown to possess good therapeutic effects in treating heart diseases and vascular diseases, such as angina pectoris, hypertension, vasoregulatoric neurasteni and certain forms of arrythmia.

Certain disadvantages have been experienced in the therapeutic use of these compounds since they block not only the B-receptors of the heart, which leads to the and attacksof asthma. For t his reason, asthma is a contraindication for heart disease treatment with the' known B-receptorblocking substances such as propanolol, alprenolol, and oxprenolol. The receptor blocking effect on blood vessels of these compounds causes adrenaline, which is released from the marrow of the suprarenal glands, to have a pure pressor effect instead of the balanced pressor-depressor effect normally maintained by adrenaline flow.

Accordingly, the main object of the invention is to provide new para-substituted phenoxy-hydroxypropylamine compounds having variable pharmacological properties which can be used in the treatment of heart diseases.

Another object of this invention is to provide new compounds which have a therapeutic effect in treating heart diseases without inducing complications due to B-blockade in bronchiand in blood vessels.

These and other closely related purposes of the present invention are achieved by administering para-substituted phenoxy-hydroxypropylamine derivatives characterized by the following generalformula:

(CH MZ v and pharmaceutically: acceptable, non-toxic acid addition salts thereof, wherein .R' is an isopropyl or tertiarybutyl radical; Z is a member' se'lected from the group consisting essentially of P", SR", and NH- COOR", R being a straight or branched chain lower alkyl radical having 1 to 3 carbon atoms; and n is l, 2, or 3.

The para-substituted phenoXy-hydroxypropylamine compounds discovered contain-an asymmetric carbon atom and, therefore, they exist as optically active forms. The racemic mixture can, of course, be resolved into its optical antipodes by well known methods, such as by using optically active acids such as tartaric acid, camphor-lO-sulphonic acid, dibenzoyl tartaric acid, and the like. Some examples of compounds according .to the, invention -are: methoxyethyl)-phenoxy]-propanol-2; propylamino-3-[p-(B-ethortyethyl)-phenoxy]- propanol-Z; l-isopropylamino-3-[p-(ethoxymethyl)- phenoxy]-p ropanol-2; l-isopropylamino-3-[p-( 'ymethoxypropyl)-phenoxy]-propanol-2; l-iso- -isopropylamino-3-[p-( B-methylrnercaptoethyl)-phenoxy]-propanol-2; and l-isopropylamino-3-[p-(B-methoxycarbonyl-amidoethyl)-phenoxy-]-propanol-2.

l-lsopropylamino-3- p-( B-methoxyethyl )-phenoxy propanol-2 and l-isopropylamino-3-[p-( B-methoxycarbonylamido-ethyl)-phenoxy]-propanol-2 are preferred both as racemates as well as in the form of their pharmacologically and optically active isomers.

The para-substituted phenoxy-hydroxypropylamines of Formula lV may be prepared by several methods which are defined as follows:

A. Reacting a compound of the formula A (CH2) Z with a compound of the formula R'NH-CNHR' (VI) in which formulas R is an isopropyl' or tertiary-butyl radical; Z is a member se'lected from the group consisting of OR", SR", and -NHCOOR", R" being a straight or branched lower alkyl radical having 1 to 3 carbon atoms; and n is l, 2, or 3. Q in Formula V represents or CHOHCH X, wherein X is a halogen atom, preferably chlorine.

B. Reacting a compound of Formula V with an amine of the formula H N-R' wherein n, Z, R, and Q have the same meaning designated above in A.

C. Alkylating a compound of the formula (VII) 1 cug z reducti'vely-by using hydrogen and'acetone to form a compound of theformula I 1 OH I (CH Z in which formulas n, and Z have the same meaning as designated in: A; j

D 'Alkylatinga compound of the formula 0- CH CH-CH --NI-I by reacting it with a compound of the formula X- (cH z wherein n, Z, and R have the same meaning as in A and R is a group which can be removed hydrolytically, preferably an acyl or a tetrahydropyranyl group.

F. Hydrolysis of a compound of the formula (CH z using a strong alkali or strong acid, wherein n, Z, and R have the same meaning as in A.

G. Hydrolysis or pyrolysis of a compound of the formula OH (XII) wherein n, Z, and R have the same meaning as above Q and R and R each represents a hydrogenatom, a

lower alkyl, aralkyl, oraryl group.

H. Hydrolysis orhydrogenolysis of a compound of the formula o-cii fcn cn -n a' d OH R0.

l fXIIlI) l Z I wherein'n, Z, and R have the same meaning as in A and R is a protecting group such as a benzyl, acety'l' or carbobenzoxy group.

l. Reacting a phenolateof the formula (XIV) o-ca -min' preferably by using a complex alkali metal hydride,

wherein n, Z, and R have the same meaning as in A and Y represents CHOHCO-- or .COCH

K. Hydrolysis of a compound of the formula (cH z any bly a phenyl group.

, If desired, the racemate s obtained [by any'i' df the' I "methods jA-Kmay be resolved intoitheir optically 'acef tive antipodes. When a pharmaceuticallyacceptable, non-toxicacid solution salt is.desired,. the compound formed-is 'refacted w ith a suitable acid. 1

The method of preparation A is preferably performed "in a higlfboilinginert, organic solvent, 'such as 1;2,3,4tetra-hydronaphthalene, decahydronaphthalene, ben'zonitrile, paraffin oil or chlorinated, aromatic organic'solvents; alternatively, the reaction may be carried out in the molten state at a temperature of 50C. 22 0C., preferably 180C. 200C.

The properties of 'the novel para-substituted phenoxy-hydroxypropylamines, particularly their selectivity in blocking the B-receptors of the heart, make themfuseful in treating heartdiseasesin animals including humanslri clinical practice the compounds of the present invention will normally be administered orally, rectally or by injection, in the form of pharmaceutical preparations comprising as the active ingredient at least one of the compounds encompassed by Formula IV as defmedherein. The active ingredients maybe used either as a free base or as a pharmaceutically acceptable non-toxic, acid addition salt, for example, the hydrochloride, lactate,'acetate,-sulfamate, and the like, in association with a pharmaceutically acceptable carrier. Accordingly, terms relating to thenovel compounds of this invention whether generically or specifically are intended to include both the free amine base and the acid addition salts of the free base, unless the context in which such terms are" used, particularly in the examples, would be inconsistent with the broad concept. The carrier may be-:a solid, semi-solid or liquid diluent or capsule. I l I 1 The pharmaceutical preparations are a further aspect of this invention. Usually'the active substance will constitute between 0.] and 95% by weight of the preparation, more specifically between 0.5 and 20% by weight "for preparation intended for injection and between 0.2

d 50%by weight for preparations suitable for oral administration. i

To produce pharmaceutical preparations containing a. compound of the invention in the form of dosage unitsfor oral' application, the selected compound may be mixed with a solid pulverulent carrier, for example, lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or ar'nylopectin, cellulose derivatives, or gelatin, and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol waxes, and the like, and then. compressed to form tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain, fdrexample, gum arabic, gelatimtalcum, titanium dioxide, and the like. Alternatively, the tablet c'anbe coated with a lacquer dissolved in a readily volatile organic solvent or mixture of organic solvents, Dyestuffs may be added to these coatings in order to readily distinguish between tablets containing different active substances or differgelatin capsules may contain granulate's of the active substance in combination with solid, pulverulent carriers such as lactose, saccharose, sorbitol, mannitol, starches (e.g., potato starch, corn starch or amylopectin), cellulose derivatives or gelatin. v

Dosage units for rectal application can be prepared in the form of suppositories comprising the active substance in admixture with a neutral fatty base, or gelatin rectal capsules comprising the active substance in admixture with vegetable oil or paraffin oil.

Liquid preparations for oral application may be in the fonn of syrups or suspensions; for example, solutions containing from about 0.2% to about 20% by weight of the active substance according to Formula IV, the balance being sugar and a mixture of ethanol, water, gylcerol, and propylene glycol. Optionally, such liquid preparations may contain coloring agents, flavoring agents, saccharine and carboxymethylcellulose as a thickening agent.

Solutions for parenteral applications by injection can be prepared in an aqueous solution of a water-soluble phannaceutically acceptable salt of the active substance preferably in a concentration of from about 0.5% to about 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules.

The following examples illustrate the principles and practices of the invention and are not intended to limit its scope in any way. All percentages are by weight unless otherwise indicated.

EXAMPLE I l,2-epoxy-3-[p-( ,B-methoxyethyl )-phenoxy]-propane 16.7 g) was dissolved in 50 ml isopropanol and mixed with 20 ml isopropylamine. The mixture was heated in an autoclave on boiling water-bath overnight, whereafter it was evaporated and the remainder dissolved in 2 N HCl. The solution was extracted first with ether and thereafter with methylene chloride. After evaporating the methylene chloride phase, the hydrochloride of 1-isopropylamino-3-[p-(B-methoxyethyl)-phenoxy]- propanol-2 was obtained which, after recrystallization from ethyl acetate, weighed 10.4 g. Melting point 83C. Equiv. weight: found 304.0, calculated 303.8. The starting material l,2-epoxy-3-[p-(B-methoxyethyl)- phenoxy]-propane was obtained from p-(B-methoxyethyl)-phenol which was reacted with epichlorohydrine whereafter the reaction product was distilled at 1 l8l28C. at a pressure of 0.35 mm Hg.

According to the method described in Example 1, the following compounds were similarly prepared as hydrochlorides.

EXAMPLE ll 1-isopropylamino-3-[ p-( B-ethoxyethyl )-phenoxy propanol-2. Melting point 102C. Equiv. weight: found 323.0, calculated 317.8. 7

EXAMPLE lll l-isopropylamino-3-( p-ethoxymethyl-phenoxy)- propanol-2. Melting point 94C. Equiv. weight: found 304.0, calculated 303.8.

EXAMPLE lV thyl )-phenoxy ]-propanol-2.

8 EXAMPLE v l-Isopropylamino-3- p-( B-methylmercaptoethyl phenoxy]-propanol-2 in base form was prepared in accordance with Example I with the exception that no reaction with hydrochloric acid took place. Melting point 60C. Equivalent weight: found 284, calculated 283.

EXAMPLE Vl l-lsopropylamino-3-[p-(y-methoxypropyl)-phenoxy]-propanol-2, melting point 89C (hydrochloride) was prepared. The starting material p-(y-methoxypropyhphenyl-glycidyl ether has a boiling point at 102l 12C and 0.03 mm Hg. Equivalent weight: found 314.0, calculated 317.8.

EXAMPLE Vll l-isopropylamino-3-[ p-( B-methoxycarbonylamidoe- Melting point 106C. Equiv. weight: found 349, calculated 347.

EXAMPLE VIII EXAMPLE 1X (Illustrating Method B) 5 g of p-(B-methoxyethyD-phenol, ml of epichlorhydrin and 0.5 ml of piperidine were heated on a boiling water bath for 10 hours. The mixture was thereafter evaporated at reduced pressure and the residue was dissolved in chloroform and was thereupon extracted with hydrochloric acid. The chloroform phase was washed with water, dried and evaporated at reduced pressure. The residue consisting of S-[p-(B- methoxy-ethyl)-phenoxy]-1-chloropropano1-2 was dissolved in 20 ml of isopropyl alcohol to which was added 10 ml of isopropylamine and the mixture was heated in an autoclave on a water bath with boiling water for 10 hours. Thereafter the mixture was evaporated and the residue was shaken with a mixture of 2/N NaOH and ether. The ether phase was dried and evaporated at reduced pressure. The residue so obtained crystallized from petroleum ether and there was thus obtained l-isopropylamino-3-[p-(,B-methoxyethyl)-phenoxy]- propanol-Z, which was converted to the hydrochloride in accordance with Example 1. The melting point of the hydrochloride was 83C.

EXAMPLE X y (Illustrating Method C) crystallized, was removed by filtration and 5 g was dissolved in 50 ml of methanol and 10 ml of acetone. The solution was cooled to 0C and 5 g of sodium borohydride was added in portions during 1 hour. Then 2.5

ml of acetone and 0.8 g of sodium borohydride were added and the solution was kept at room temperature for 1 hour whereupon 150 ml of B was added. The mixture was extracted with ether whereupon the ether phase was dried over potassium carbonate and evaporated. The residue was transformed to the hydrochloride by dissolving the base in ethyl acetate and introducing gaseous HCI into the solution. In this way the hydrochloride of l-isopropylarnino-3-[p-( ,B-methoxyethyl)-phenoxy]-propanol-2 was obtained having a melting point of 83C.

EXAMPLE XI (Illustrating Method D) A solution of g of p-(B-ethoxyethyU-phenyl glycidyl ether in 100ml of ethanol was saturated with ammonia whereupon the mixture was heated upon a water bath containing boiling water for 4 hours. Thereafter the reaction mixture was evaporated and the residue dissolved in ethyl acetate. HCl in gaseous form was introduced causing the amine hydrochloride to crystallize. The crystals were removed by filtration and dissolved in 70 ml of ethanol whereupon 10 ml of iso propylbromide and 12 g of potassium carbonate was added. The mixture was heated in an autoclave atl20C for 10 hours whereupon the ethanol was removed by evaporation. To the residue was added 100 ml of 2/N HCl and 100 ml of ether. The water phase was separated and alkalized with 2/N NaOH and thereupon extracted with ethyl acetate. The ethyl acetate phase was dried by means of potassium carbonate whereupon gaseous HCl was introduced. This caused crystallization of the hydrochloride which was separated by filtration and recrystallized from methylethylketone. There was thus obtained the hydrochloride of l-isopropylamino-3-[ p-( ,B-ethoxyethyl )-phenoxy] propanol-Zhaving a melting point of 102C.

EXAMPLE XII (Illustrating Method E) A solution of 8 g of 3-[p-(B-ethoxyethyl)-phenoxy1- l-chloropropanol-2 (prepared for instance according to method B) in 15 ml of dihydropyran was mixed with a small amount of p-toluene sulphonic acid. This caused an increase of the temperature to 50C and after having been kept at this temperature for 30 minutes the mixture was dissolved in 100 ml of ethanol whereupon 10 ml of isopropylamine was added. The reaction was heated in an autoclave for 10 hours on steam bath and was thereafter evaporated. The residue was dissolved in ethyl acetate to which was added oxalic acid and was thereupon diluted with ether. The crystallized oxalate was separated and recrystallized from ethanol/ether. To the oxalate was added 50 ml of 2/N HCl and the mixture was heated on water bath for 15 minutes. After cooling the mixture was alkalized by addition of NaOH and the base was extracted with ether. The ether phase was dried and evaporated whereafter the residue was dissolved in ethyl acetate followed by introduction of gaseous HCl. The precipitate thus obtained was recrystallized from methylethylketone which gave the hydrochloride of l-isopropylamino-3-[p-(B-ethoxyethyl)-phenoxy]- propanol-2 having a melting point of l03C.

, EXAMPLE Xlll (Illustrating Method F) 5.5 g of 3-isopropyl-5-[p-(B-methoxyethyl)-phenoxymethyl]-oxazolidinone-2was dissolved in 60 ml of ethanol to which was added a solution of 9 g of KOI-l in l5 ml of H 0. The mixture was refluxed, was thereupon evaporated and the residue dissolved in 2/N HCl and extracted with ether. The water phase was alkalized with NaOH and extracted with ether. After drying by means of potassium carbonate, gaseous HCl was introduced, causing the hydrochloride of l-isopropylamino- 3 [p-( B-methoxyethyl )-phenoxy ]-propanol-2to crystallize. The hydrochloride gave after recrystallization from methylethyl ketone, a melting point of 83C.

EXAMPLE XlV (Illustrating Method A and G) 4.5 g of p-(B-ethoxyethyD-phenyl glycidyl ether was dissolved in 50 ml of tetralin to which was added 5.7 g of N,N'-diisopropylurea and 20 g of lithium hydroxide whereupon the mixture was heated at 200C for 3 hours. The reaction mixture was after cooling diluted with 50 ml of ether and shaken with ml of 2/N I-lCl. The water phase was extracted with ether and thereupon alkalized by addition of NaOH and was finally shaken with ether. The ether phase was washed with water, dried and evaporated. The residue was dissolved in ethyl acetate and the hydrochloride precipitated by addition of a solution of gaseous BC] in ether. The hydrochloride of l-isopropylamino-3-[p-(B-ethoxyethyl)-phenoxy]-propanol-2with a melting point of 102C was obtained after recrystallization from methylethyl ketone.

EXAMPLE xv (Illustrating Method H and l) 0.92 g of Na was dissolved in 50 ml of alcohol and to the solution wasadded 6.1 gof p-(B-methoxyethyD- phenol 9.6 g of 3-(N-benzyl-N-isopropylamino)-lchloropropanol-2. The mixture was heated in an autoclave on steam bath overnight and was thereupon filtered and evaporated to dryness. To the residue was added 100 ml of 2/N HCl and the mixture was extracted with ether whereupon. the water phase was alkalized by addition of NaOH and thereupon shaken with ether. The ether phase was dried and evaporated and the residue obtaineddissolved in 200 ml of alcohol and neutralized with concentrated l-ICl. To this solution was added 0.5 g of Pd/C catalyst and the reaction mixture was hydrogenated at. atmospheric pressure until the calculated amountofH had been consumed. After filtering, the reaction mixture was evaporated to dryness and the residue thereupon recrystallized from methylethylketone giving the hydrochloride of l-isopropylamino-3-[p-(B-methoxyethyl)-phenoxy[- propanol-2, having a melting point of 83C.

EXAMPLE XVI (lllustrating Method J) 15.2 g of p(fil'methoxyethyl)'-phenol was dissolved in a solution of 4.6 g of Na in 100 ml of ethanol. To the solution was added 12.5 g of 2-hydroxy-3-chloropropionic acid and the mixture was refluxed for 3 hours. The mixture was thereupon evaporated and to the residue was added 100 ml of 2/N HCl and the resulting mixture was thereupon extracted with benzene. The benzene phase was shaken with sodium bicarbonate solution which was thereupon acidified by addition of HCl followed by an extraction with benzene. After EXAMPLE XVII (Illustrating Method K) To g of N-isopropyl-N-[3-[p-(B-methoxyethyl)- phenoxy]-2-hydroxypropyl]carbamic acid ethyl ester was added 25 ml of 2/NHCl and the mixture was heated on water bath for 2 hours. After cooling, the

mixture was extracted with ether and the water phase was alkalized by addition of NaOH, followed by an extraction with ether. After drying and evaporation and recrystallization from petroleum ether, l-isopropylamino-3-[p-(B-methoxyethyl)-phenoxy]- propanol-Z was obtained having a melting point of 83C, (hydrochloride).

EXAMPLE VIII (Method other than A-K) I-Isopropylamino-3-[p-(y-aminopropyl )-phenoxy propanol-2-di-HCI (3.4 g) was dissolved in ml H O. Sodium bicarbonate (2.6 g) was added to the solution and aftera few minutes while stirring, 1.0 g of methyl chloroformate was added. The mixture was stirred overnight at room temperature, followed by extraction with methylene dichloride. The methylene dichloride phase was dried with K CO filtered and evaporated.

In this way the base form of l-isopropylamino-3-[p-(ymethoxycarbonylamidopropyl)-phenoxy]-propanol 2- was obtained (m.p. =72C). Equivalent weight: Found 329; calculated 324. a I a The starting material, 1-isopropylamino- 3-[p-(yamino-propyl)-phenoxy]-propanol-2, was prepared in the following manner: p-(B-cyanoethyhphenol (100.9 g), 149.] g epichlorohydrin, 226 g K CO and 700 ml acetonitrile were mixed and refluxed while stirring overnight.

After filtration, the filtrate was evaporated in vacuo.

The residue (1 15 g) was dissolved in 300 ml of isopro- I panol; 300 ml of isopropylamine was added, whereupon the mixture was refluxed for 3 hours. After evaporation in vacuo 138.5 g of an oil was obtained. 8.5 g of this oil was dissolved in 500 ml of ethanol 99%) and 8.5 ml of cone. HCI was added, followed by hydrogenation at 3.5 atm. (0.5 g. Pd/C as a catalyzing agent) until the calculated amount of hydrogen was consumed. After filtration, evaporation and recrystallization from alcohoL the dihydrochloride of l-isopropylamino-3-[p- ('y-aminopropyl)-phenoxy]propanol-2 (mp. 180C) was obtained.

12 EXAMPLE XIX According to the method described in Example XVIII the compound l-tert.-butylamino-3-[p-(B- methoxycarbonylamidoethyl )-phenoxy propanol-2 was prepared (m.p.=92C in base form; Equivalent weight: found 325; calculated 324). The compound 1-tert.-butylamino-3'[p-(Baminoethyl)-phenoxy]- propanol-2-di-HC1 (m.p.=192C) was used as starting material. This latter compound was prepared according to the method described in Example XVIII using pcyanomethylphenol and tert.-butylamine as starting materials.

PHARMACOLOGICAL EVALUATION Compounds prepared according to the examples were evaluated for intrinsic activity and blocking effect on heart rate and peripheral vasodilator response to isoprenaline in the cat. The acute LD in mice was evaluated. Alprenolol was used as a reference substance.

Cats weighing between 1.8 and 2.8 kg were anaesthetized with mg/kg pentobarbital sodium, intraperitoneally. The cats had been pretreated with reserpine, 5 mg/kg intramuscular, about 18 hours before the experiment. Bilateral vagotomy was performed before the start of the experiment.

The heart rate was recorded on an Offner cardiotachometer triggered by the EKG-complex. Mean aiterial blood pressure was recorded from a carotid artery. The peripheral resistance was measured in one of the legs of the cat in the following way: The femoral artery was opened in the inguinal region and the leg was perfused by blood delivered through a sigma motor pump at constant rate. The flow resistance (the pressure) was recorded via a pressure transducer connected to the catheter distally to the pump. The paw was excluded from the circulation by a tight ligature Intravenously .injected isoprenaline increased the heart rate and reduced the perfusion pressure. An isoprenaline dose giving -80% of the maximal chronotropic response was determined. This dose (usually 0.1 ug/kg) was then repeated with 20 minute intervals. Ten minutes before each isoprenaline injection, the tested substances were administered intravenously for two minutes, starting with a dose of 0.01 mg/kg and increasing each subsequent dose fourfold. The intrinsic effects of the test substances were determined. The dose producing 50% blockade of the isoprenaline responses was evaluated from the plotted log dose-per cent blockade diagrams.

Table I shows the results of the foregoing experiments for intrinsic stimulating activity on heart rate in cats, B-blocking activity on heart rate and peripheral vascular resistance in cats and LD after intraperitoneal administration in mice.

I O-CH2CHCH2NHCH (CH3 2 (XVIII) TABLE I g p I Compounds Tested 7 Reserpinized ,cat Mouse Intrinsic B-blockade B-block-, 1 activity Heart rate: ade (CI-I ),,Z of maximal ED mg/kg peripheral LD isoprenaline' vascular i.p.' A (except allyl) heart rate resistance m kg r I g ED mg/kg o-allyl (alprenolol) 20 1 0.1 0.05 I CH3OCH2CH2-(EX. I) 1 0 0.4 3 200 C H OCH CH (Ex. II) 0 0.3 4 I50 C H OCI-I (Ex.Ill); 0 0.4 6 175 CH OC--NHCH CH 1 V 1 (Ex. VII) 0.4 19 125 I w o v i C H OCNHCHJ CI-I 0 0.3 '200 0 (EX.VII|) The results reported in Table: I, show that the EXAMPLE XXII phenoxy-hydroxypropylamine test substances according to the invention were 34.tirnes less active than alprenolol, the standardreference, as regards blockade of the B-receptors of theheart. The peripheralvascular j A granulate was prepared from 1-isopropylamino-3- B-blocking activity for the test substances was 60-500 times lower than. the activity of alprenolol. These re sults demonstrate that the test substances, developed a relatively stronger blockade of the B-r eceptors of the heart than of the receptors in smooth muscles. Due to this cardioselectivity, the compounds according to the invention give therapeutic effects in treating cardiovascular diseases without risk or complications due to ,B-blockade in bronchi and blood vessels.

The following examples illustrate methods of preparing some pharmaceutical preparations according to the invention.

EXAMPLE XX A syrup containing 2% (weight per volume) of active substance according to the invention was produced from the following ingredients:

1-isopropylamino-3-(p-methoxyethyl-phenoxy) propanol-2 [HCI] 2.0 g Saccharin 0.6 g Sugar 30.0 g Glycerol 5.0 g Flavoring agent 0.1 g Ethanol'(96%) 10.0 ml to 100.0 ml

Distilled water (balance) The sugar, saccharin and the ether salt were dissolved in 60 grams of hot water. After cooling, the glycerol was added and a solution of the flavoring agent in ethanol was added. The mixture was then made up to a volume of 100 milliliters with water.

The active substance in this composition may be replaced by other pharmaceutically acceptable, nontoxic acid addition salts.

EXAMPLE XXI (ethoxymethyl-phenoxy)-propanol-2 hydrochloride (250 g), lactose (175.9 g) and an alcoholic solution of polyvinyl pyrrolidone (25 g). After drying, the granulate was mixed wit talc 25 g potato starch 40 g) and magnesium stearate (2.50 g) and pressed into 10,000 biconvex tablets. These tablets were first coated with'a 10% alcoholicshellacsolution and then with a water solution containing saccharose (45%), gum arabic (5%), gelatin (4%) and dyestuff (0.2%). Talc and sugar powder were used as dusting powders after the first 15 applications. The coating was then finished with a 66% sugar syrup andpolished with a 10% carnauba wax solution in carbon tetrachloride.

EXAMPLE XXIII l isopropyla'mino-3-(p-methoxyethylphenoxy propanol-Z hydrochloride (1g),s0dium chloride (0.8 g)and ascorbic acid (0.1 g) were dissolved in sufficient distilled water to make milliliters of solution. This solution, eachmilliliter of which contained 10 milligrams of the active substance, was used to fill amp'oules which were sterilized by heating for 20 minutes at C.

Many obvious variations of the invention disclosed will suggest themselves to those skilled in the art. Nothing in the preceding specification is intended, however, to limit the scope of "the invention as defined by the following claims.

We claim:

l. A pharmaceutical preparation for treatment of cardiovasculardiseases which comprises as an active ingredient a therapeutically effective dose .of at least one para-substituted phenoxy-hydroxypropylamine compound selected from the group consistingof a'compound having the formula (cH z and a pharmaceutically acceptable, non-toxic acid addition salt thereof, wherein R is an isopropyl or tertiary-butyl radical; Z is NHCOOR", R" being a straight or branched alkyl radical having 1 to 3 carbon atoms and n is l, 2 or 3, in association with a pharmaceutically acceptable carrier.

2. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound in racemic form.

3. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound as the optically active, dextrorotatary isomer.

4. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound as the optically active, levorotatary isomer.

5. A pharmaceutical preparation according to claim 1 wherein the para-substituted phenoxy-hydroxypropylamine compound comprises 0.1 to 95% by weight of the preparation.

6. A pharmaceutical preparation according to claim 1 in a form suitable for administration by injection wherein the para-substituted phenoxy-hydroxypropylamine compound comprises about 0.5% to about by weight of the preparation.

7. A pharmaceutical preparation according to claim 6 for parenteral application which comprises an aqueous solution of a water soluble salt of said para-substituted phenoxy-hydroxy-propylamine compound in an amount of about 0.5 10% by weight of the preparation.

8. A pharmaceutical preparation according to claim 1 in a form suitable for oral administration wherein the para-substituted phenoxy-hydroxypropylamine compound comprises about 0.2% to about 50% by weight of the preparation.

9. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein R is isopropyl in association with a pharmaceutically acceptable carrier.

10. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein R is tertiarybutyl in association with a pharmaceutically acceptable carrier.

1 l. A pharmaceutical preparation wherein the active ingredient is the compound of claim I (i) -l-isopropylamino phenoxyl-propanol-Z and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.

12. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 ()-l-isopropylamino -3-[p-( B-methoxycarbinylamidoethyl phenoxy]-propanol-2 and a pharmaceutically accept- -3-[ p-( B-methoxycarbinylamidoethyl able, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.

13. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 (+).-l-isopropylamino-1H p-( B-methoxycarbinamidoethyl phenoxy]-propanol-2 and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.

14. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 l-isopropylamino-3-[p-( 'y-methoxycarbonylamidopropyl)- phenoxy]-propanol-2 and a phannaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.

15. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 l-tertiarybutylamino-3- p-( B-methoxycarbinylamidoethyl phenoxy]-propanol-2 and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.

16. A method for treating cardiovascular diseases in animals including humans which comprises administering a therapeutically effective dose of a para-substituted phenoxyhydroxypropylamine compound selected from the group consisting essentially of a compound having the formula (cH z and a pharmaceutically acceptable, non-toxic acid addition salt thereof, wherein R is an isopropyl or tertiary-butyl radical; Z is -NHCOOR", R being a straight or branched alkyl radical having 1 to 3 carbon atoms: and n is l, 2 or 3, in association with a pharmaceutically acceptable carrier.

17. A method for treating cardiovascular diseases in animals including humans, which comprises administering a therapeutically effective dose of a parasubstituted phenoxyhydroxypropylamine compound according to claim 16 wherein R is isopropyl.

18. A method for treating cardiovascular diseases in animals including humans, which comprises administering a therapeutically effective dose of a parasubstituted phenoxyhydroxypropylamine compound according to claim 16 wherein R is tertiarybutyl.

'UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3,928,601 DATED 1 December 23, 1975 INVENTOR(S) Arne Elof Brandstr'om et a1 It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below;

Front page, insert the following Item after Item [60] -'-[30] Foreign Application Priority Data Feb. 18, 1970 Sweden 2050/70-.

Signed and Scaled this Twentieth Day Of July 1976 [SEAL] Arrest:

RUTH C. MASON C. MARSHALL DANN Arresting Officer Commissioner oj'Parents and Trademarks 

1. A pharmaceutical preparation for treatment of cardiovascular diseases which comprises as an active ingredient a therapeutically effective dose of at least one para-substituted phenoxy-hydroxypropylamine compound selected from the group consisting of a compound having the formula
 2. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound in racemic form.
 3. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound as the optically active, dextrorotatary isomer.
 4. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound as the optically active, levorotatary isomer.
 5. A pharmaceutical preparation according to claim 1 wherein the para-substituted phenoxy-hydroxypropylamine compound comprises 0.1 to 95% by weight of the preparation.
 6. A pharmaceutical preparation according to claim 1 in a form suitable for administration by injection wherein the para-substituted phenoxy-hydroxypropylamine compound comprises about 0.5% to about 20% by weight of the preparation.
 7. A pharmaceutical preparation according to claim 6 for parenteral application which comprises an aqueous solution of a water soluble salt of said para-substituted phenoxy-hydroxy-propylamine compound in an amount of about 0.5 - 10% by weight of the preparation.
 8. A pharmaceutical preparation according to claim 1 in a form suitable for oral administration wherein the para-substituted phenoxy-hydroxypropylamine compound comprises about 0.2% to about 50% by weight of the preparation.
 9. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein R'' is isopropyl in association with a pharmaceutically acceptable carrier.
 10. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein R'' is tertiarybutyl in association with a pharmaceutically acceptable carrier.
 11. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 ( + or - ) -1-isopropylamino -3-(p-( Beta -methoxycarbinylamidoethyl)-phenoxy)-propanol-2 and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.
 12. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 (-)-1-isopropylamino -3-(p-( Beta -methoxycarbinYlamidoethyl)-phenoxy)-propanol-2 and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.
 13. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 (+)-1-isopropylamino-3-(p-( Beta -methoxycarbinamidoethyl)-phenoxy)-propanol-2 and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.
 14. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 1-isopropylamino-3-(p-( gamma -methoxycarbonylamidopropyl)-phenoxy)-propanol-2 and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.
 15. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 1-tertiarybutylamino-3-(p-( Beta -methoxycarbinylamidoethyl)-phenoxy)-propanol-2 and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.
 16. A METHOD FOR TREATING CARDIOVASCULAR DISEASES IN ANIMALS INCLUDING HUMANS WHICH COMPRISES ADMINISTERING A THERAPEUTICALLY EFFECTIVE DOSE OF A PARA-SUBSTITUTED PHENOXYHYDROSYPROPYLAMINE COMPOUND SELECTED FROM THE GROUP CONSISTING ESSENTIALLY OF A COMPOUND HAVING THE FORMULA
 17. A method for treating cardiovascular diseases in animals including humans, which comprises administering a therapeutically effective dose of a parasubstituted phenoxyhydroxypropylamine compound according to claim 16 wherein R'' is isopropyl.
 18. A method for treating cardiovascular diseases in animals including humans, which comprises administering a therapeutically effective dose of a parasubstituted phenoxyhydroxypropylamine compound according to claim 16 wherein R'' is tertiarybutyl. 